Last edition
News about
Kazia Therapeutics Limited, a Sydney-based oncology-focused drug development company, has entered into an exclusive collaboration and in-licensing agreement with QIMR Berghofer to advance a pioneering PD-L1 degrader programme.
The facility was already US FDA-registered as a medical device establishment, supporting a portfolio of 510(k)-cleared products across multiple therapeutic categories.
Chugai Pharma concludes licence agreement with Roche for CT-388
Chugai Pharmaceutical has signed a licensing deal with F. Hoffmann-La Roche for CT-388, a long-acting GLP-1/GIP receptor agonist for obesity and type-II diabetes, granting Chugai exclusive development and marketing rights in Japan.
GKB Ophthalmics Cuts Production at Goa Plant Amid Sluggish Market Demand
GKB Ophthalmics has reduced production to 50 percent at its Tivim Industrial Estate plant in Mapusa, Goa, due to a slowdown in market demand and the complete suspension of export orders from its US subsidiary starting October 2025, following the imposition of heavy tariffs.
US FDA Completes Pre-Approval Inspection at Lupin's Somerset Facility with One Observation
The US Food and Drug Administration (FDA) has completed a pre-approval inspection of Lupin’s manufacturing facility in Somerset, New Jersey, USA, with one observation.
Celltrion Receives US FDA Approval for EYLEA Biosimilar EYDENZELT
Celltrion has received approval from the US Food and Drug Administration (FDA) for EYDENZELT (aflibercept-boav), a biosimilar to EYLEA (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR).
Johnson & Johnson MedTech Launches CORE-VA Registry to Advance Ventricular Arrhythmia Care
Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, has unveiled a new initiative aimed at improving outcomes for patients with life-threatening heart rhythm disorders.
AstraZeneca has announced a historic agreement with President Donald Trump’s administration to lower the cost of prescription medicines for American patients while strengthening the nation’s biopharmaceutical innovation base.
Shuttle Pharmaceuticals Signs LOI to Acquire Molecule.ai in USD 10 Million Deal
US-based specialty pharmaceutical company Shuttle Pharmaceuticals Holdings has signed a non-binding Letter of Intent (LOI) to acquire Molecule.ai, an advanced artificial intelligence firm revolutionising drug discovery and development.
Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy